MyFinsight
Home
Blog
About
Contact
Download
Download image
Redemptions of marketable
securities
$25,780,771
Proceeds from the
issuance of common stock...
$1,624,547
Proceeds from option
exercises
$13,442
Net cash flows
provided by investing...
$11,057,073
Net cash flows
provided by financing...
$1,498,240
Effect of foreign
exchange rates on cash
$33,426
Canceled cashflow
$14,723,698
Canceled cashflow
$139,749
Change in cash and cash
equivalents for the year
-$3,088,241
Canceled cashflow
$12,588,739
Stock-based compensation
$650,877
Prepaid expenses & other
current assets
-$554,095
Issuance of restricted
common stock for...
$366,900
Accounts payable and
accrued expenses
$271,808
Realized loss on equity
securities
$264,913
Non-cash lease
adjustments
$189,897
Depreciation and
amortization
$17,280
Purchase of marketable
securities
$14,721,983
Purchase of property and
equipment
$1,715
Payments of offering cost
related to the atm sales...
$139,749
Net cash flows used
in operating...
-$15,676,980
Canceled cashflow
$2,315,770
Net loss
-$17,119,438
Unrealized gain on equity
securities
$305,887
Accretion of discounts on
available for sale debt...
$196,427
Operating lease
liabilities
-$190,625
Foreign currency
remeasurement (gain) loss
$157,965
Realized gain on
redemptions of available for...
$22,408
Back
Back
Cash Flow
source: myfinsight.com
Lantern Pharma Inc. (LTRN)
Lantern Pharma Inc. (LTRN)